About the Company

Aeglea BioTherapeutics (NasdaqGM: AGLE) is a biotechnology company developing enzyme-based treatments for patients with inborn errors of metabolism and cancer. The Company employs protein engineering to create more active enzymes with higher stability. Lead candidate AEB1102 is a pegylated human arginase I designed to deplete arginine in the blood. In the third quarter of 2016, Aeglea is planning to initiate a Phase I trial with AEB1102 in patients with arginase I deficiency, and is currently conducting a Phase I trial in patients with arginine-dependent cancer. Aeglea has a pipeline of additional candidates based on its biochemistry expertise and ability to engineer enzymes. The Company completed a $47.3 million IPO in April 2016 and is now trading under the ticker AGLE.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research